Population Pharmacokinetic Modeling of Steady State Carbamazepine Clearance in Children, Adolescents, and Adults

被引:0
|
作者
David M. Reith
Wayne D. Hooper
John Parke
Bruce Charles
机构
[1] Centre for Studies in Drug Disposition,
[2] Centre for Studies in Drug Disposition,undefined
来源
Journal of Pharmacokinetics and Pharmacodynamics | 2001年 / 28卷
关键词
carbamazepine; NONMEM; clearance; population pharmacokinetics; surface area;
D O I
暂无
中图分类号
学科分类号
摘要
Carbamazepine (CBZ) clearance decreases from childhood to adulthood and the factors determining this change could include age, size, autoinduction, or maturational changes. This study aims to describe the population pharmacokinetics of CBZ in children and young adults and test the hypothesis that CBZ clearance correlates with weight, surface area, and age. CBZ therapeutic drug monitoring data (sparse data) were collected from child and adult epileptics, and rich data were obtained from a bioequivalence study of CBZ in young adults. Population pharmacokinetic analysis was performed using NONMEM V. Forward stepwise, multiple regression was performed on the covariates. Bootstrap validation was performed. A total of 946 observations from 91 subjects, ages 0.7–37 years, were collected and analyzed. A one-compartment, first-order absorption and elimination model, with exponential interindividual error and additive residual error models was developed. The population model was: Clearance (Lhr−1)=((2.24 · Surface area (m2))+(0.047 · Dose (mg · kg−1)); Volume of distribution (L)=0.37 · weight (kg); Absorption rate constant=0.013 (hr−1). CBZ clearance increased with surface area and dose.
引用
收藏
页码:79 / 92
页数:13
相关论文
共 49 条
  • [1] Population pharmacokinetic modeling of steady state carbamazepine clearance in children, adolescents, and adults
    Reith, DM
    Hooper, WD
    Parke, J
    Charles, B
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2001, 28 (01) : 79 - 92
  • [3] Population pharmacokinetic modeling of steady state clearance of carbamazepine and its epoxide metabolite from sparse routine clinical data
    Jiao, Z
    Shi, XJ
    Zhao, ZG
    Zhong, MK
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2004, 29 (03) : 247 - 256
  • [4] Factors influencing carbamazepine pharmacokinetics in children and adults: population pharmacokinetic analysis
    Milovanovic, J. R.
    Jankovic, S. M.
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2011, 49 (07) : 428 - 436
  • [5] Effect of patient weight and carbamazepine daily dose on carbamazepine clearance-a population pharmacokinetic study
    Vucicevic, Katarina
    Miljkovic, Branislava
    Pokrajac, Milena
    Grabnar, Iztok
    PHARMACY WORLD & SCIENCE, 2009, 31 (02): : 332 - 333
  • [6] Population pharmacokinetics of steady-state carbamazepine in Egyptian epilepsy patients
    EL Desoky, E. S.
    Sabarinath, S. N.
    Hamdi, M. M.
    Bewernitz, M.
    Derendorf, H.
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 2012, 37 (03) : 352 - 355
  • [7] Pharmacokinetic Interaction of Single Dose of Piperine with Steady-state Carbamazepine in Epilepsy Patients
    Pattanaik, Smita
    Hota, Debasish
    Prabhakar, Sudesh
    Kharbanda, Parampreet
    Pandhi, Promila
    PHYTOTHERAPY RESEARCH, 2009, 23 (09) : 1281 - 1286
  • [8] Maturation of midazolam clearance in critically ill children with severe bronchiolitis: A population pharmacokinetic analysis
    Kos, Mojca Kerec
    Miksic, Mirjana
    Jovanovic, Marija
    Roskar, Robert
    Grosek, Stefan
    Grabnar, Iztok
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2020, 141
  • [9] Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine
    Zhou, Wangda
    Li, Jianguo
    Birmingham, Bruce
    Xu, Hongmei
    Lillieborg, Stefan
    Zhou, Diansong
    Al-Huniti, Nidal
    JOURNAL OF CLINICAL PHARMACOLOGY, 2017, 57 (10) : 1258 - 1267
  • [10] A Population Pharmacokinetic Model for Montelukast Disposition in Adults and Children
    Rohini Ramakrishnan
    Elizabeth Migoya
    Barbara Knorr
    Pharmaceutical Research, 2005, 22 : 532 - 540